[go: up one dir, main page]

MX2016010519A - Moleculas para administracion a celulas cancerosas mutantes ros1. - Google Patents

Moleculas para administracion a celulas cancerosas mutantes ros1.

Info

Publication number
MX2016010519A
MX2016010519A MX2016010519A MX2016010519A MX2016010519A MX 2016010519 A MX2016010519 A MX 2016010519A MX 2016010519 A MX2016010519 A MX 2016010519A MX 2016010519 A MX2016010519 A MX 2016010519A MX 2016010519 A MX2016010519 A MX 2016010519A
Authority
MX
Mexico
Prior art keywords
ros1
administration
molecules
cancer cells
mutant cancer
Prior art date
Application number
MX2016010519A
Other languages
English (en)
Other versions
MX373042B (es
Inventor
Lim Jonathan
Ardina Elena
Menichincheri Maria
Original Assignee
Ignyta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ignyta Inc filed Critical Ignyta Inc
Publication of MX2016010519A publication Critical patent/MX2016010519A/es
Publication of MX373042B publication Critical patent/MX373042B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se exponen derivados de indazol sustituido de la fórmula (I) o la fórmula 2. (I) y sales farmacéuticamente aceptables de los mismos, como se definen en la especificación, un proceso para su preparación y composiciones farmacéuticas que los comprenden; los compuestos de la invención pueden ser útiles en terapia en el tratamiento de enfermedades asociadas con una actividad desregulada de la proteína cinasa, como el cáncer.
MX2016010519A 2014-02-20 2015-02-19 Moleculas para administracion a celulas cancerosas mutantes ros1. MX373042B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461942287P 2014-02-20 2014-02-20
US201462052994P 2014-09-19 2014-09-19
US201462055450P 2014-09-25 2014-09-25
US201462069999P 2014-10-29 2014-10-29
PCT/EP2015/053544 WO2015124697A1 (en) 2014-02-20 2015-02-19 Compounds for treating patients with ros1 mutant cancer cells

Publications (2)

Publication Number Publication Date
MX2016010519A true MX2016010519A (es) 2016-11-16
MX373042B MX373042B (es) 2020-06-19

Family

ID=52544499

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016010519A MX373042B (es) 2014-02-20 2015-02-19 Moleculas para administracion a celulas cancerosas mutantes ros1.

Country Status (20)

Country Link
US (4) US10231965B2 (es)
EP (2) EP3834827A1 (es)
JP (1) JP6636933B2 (es)
KR (2) KR102634514B1 (es)
CN (1) CN106029073A (es)
AU (1) AU2015220832B2 (es)
BR (1) BR112016015818A2 (es)
CA (1) CA2933623C (es)
CL (1) CL2016001507A1 (es)
EA (1) EA033457B1 (es)
ES (1) ES2856231T3 (es)
IL (1) IL246544B (es)
MX (1) MX373042B (es)
NL (1) NL301111I2 (es)
PH (1) PH12016501394A1 (es)
PL (1) PL3107541T3 (es)
SG (1) SG11201605816TA (es)
TW (1) TWI672141B (es)
UA (1) UA118773C2 (es)
WO (1) WO2015124697A1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8450322B2 (en) 2008-09-22 2013-05-28 Array Biopharma Inc. Substituted imidazo[1,2b]pyridazine compounds as Trk kinase inhibitors
KR102037619B1 (ko) 2008-10-22 2019-10-28 어레이 바이오파마 인크. ＴＲＫ 키나아제 억제제로서 치환된 피라졸로［１,５­ａ］ 피리미딘 화합물
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
ES2628418T3 (es) 2010-05-20 2017-08-02 Array Biopharma, Inc. Compuestos macrocíclicos como inhibidores de la TRK cinasa
ES2853485T3 (es) 2013-02-19 2021-09-16 Ono Pharmaceutical Co Derivado de urea como compuesto inhibidor de Trk
TWI672141B (zh) 2014-02-20 2019-09-21 美商醫科泰生技 投予ｒｏｓ１突變癌細胞之分子
CA2967951C (en) 2014-11-16 2023-11-07 Array Biopharma, Inc. Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
AU2015355220B2 (en) 2014-12-02 2020-02-27 Ignyta, Inc. Combinations for the treatment of neuroblastoma
US20170356918A1 (en) * 2014-12-03 2017-12-14 Ignyta, Inc. Multiplexed immunohistochemistry assays for diagnosis and treatment of cancer
BR112017025773A2 (en) 2015-06-01 2018-08-14 Loxo Oncology, Inc. cancer diagnosis and treatment methods
WO2017011776A1 (en) 2015-07-16 2017-01-19 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
CN108697708A (zh) 2015-10-26 2018-10-23 洛克索肿瘤学股份有限公司 Trk抑制剂抗性癌症中的点突变以及与此相关的方法
EP3389645A4 (en) * 2015-12-18 2019-12-18 Ignyta, Inc. COMBINATIONS FOR TREATING CANCER
SI3439662T1 (sl) 2016-04-04 2024-11-29 Loxo Oncology, Inc. Tekoče formulacije (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirolidin -1-il)-pirazološ1,5-aćpirimidin-3-il)-3-hidroksipirolidin-1-karboksamida
HRP20241295T1 (hr) 2016-04-04 2024-12-06 Loxo Oncology, Inc. Postupci za liječenje pedijatrijskih karcinoma
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
DK3458456T3 (da) 2016-05-18 2020-12-14 Array Biopharma Inc Fremstilling af (s)-n-(5-((r)-2-(2,5-difluorphenyl)pyrrolidin-1-yl)pyrazol[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidin-1-carboxamid
PL3464276T3 (pl) 2016-05-24 2022-04-04 Nerviano Medical Sciences S.R.L. Nowa postać krystaliczna n-[5-(3,5-difluoro-benzylo)-1h-indazol-3-ilo)-4-(4-metylopiperazyn-1-ylo)-2-tetrahydropiran-4-yloamino)-benzamidu
WO2018026663A1 (en) * 2016-08-01 2018-02-08 Ignyta, Inc. Combinations for the treatment of cancer
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
EP3571203B1 (en) 2017-01-18 2023-06-07 Array BioPharma Inc. Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
JP7203083B2 (ja) * 2017-07-19 2023-01-12 イグナイタ インコーポレイテッド エントレクチニブを含む薬学的組成物
US10180422B1 (en) 2017-08-22 2019-01-15 Scripps Health Methods of treating a neuroendocrine tumor
TWI876442B (zh) 2017-10-10 2025-03-11 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
JP7311498B2 (ja) * 2017-10-17 2023-07-19 イグナイタ インコーポレイテッド 薬学的組成物および剤形
WO2019084285A1 (en) 2017-10-26 2019-05-02 Qian Zhao FORMULATIONS OF A MACROCYCLIC TRK KINASE INHIBITOR
WO2019143994A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
EP3740490A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
WO2019143977A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CA3095366A1 (en) 2018-03-29 2019-10-03 Loxo Oncology, Inc. Treatment of trk-associated cancers
WO2020028258A1 (en) 2018-07-31 2020-02-06 Loxo Oncology, Inc. Spray-dried dispersions and formulations of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoro propan-2-yl)-1h-pyrazole-4-carboxamide
EP3849986B1 (en) 2018-09-10 2022-06-08 Array Biopharma, Inc. Fused heterocyclic compounds as ret kinase inhibitors
JP2022515197A (ja) 2018-12-19 2022-02-17 アレイ バイオファーマ インコーポレイテッド がんを治療するためのｆｇｆｒ阻害剤としての７－（（３，５－ジメトキシフェニル）アミノ）キノキサリン誘導体
WO2020131627A1 (en) 2018-12-19 2020-06-25 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
JPS6041489A (ja) 1983-08-12 1985-03-05 Kyowa Hakko Kogyo Co Ltd 新規生理活性物質ｋ―２５２
AU2882699A (en) 1998-02-27 1999-09-15 Watson Pharmaceuticals, Inc. Stabilizing composition for pharmaceutical dosage forms
JP2002275068A (ja) 2001-03-16 2002-09-25 Kyowa Hakko Kogyo Co Ltd アポトーシス誘導剤
WO2003027111A1 (en) 2001-09-27 2003-04-03 Smithkline Beecham Corporation Chemical compounds
AU2002353186A1 (en) 2001-12-19 2003-06-30 Smithkline Beecham P.L.C. (1-h-indazol-3-yl) -amide derivatives as gsk-3 inhibitors
FR2836915B1 (fr) 2002-03-11 2008-01-11 Aventis Pharma Sa Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
AU2003251875A1 (en) 2002-07-15 2004-02-02 Combinatorx, Incorporated Combination therapy for the treatment of neoplasms
BR0314098A (pt) 2002-09-05 2005-07-19 Aventis Pharma Sa Derivados da aminoindazóis a tìtulo de medicamentos e composições farmacêuticas que os contêm
MXPA05005554A (es) 2002-12-12 2005-07-26 Aventis Pharma Sa Derivados de aminoindazol y su utilizacion como inhibidores de quinasas.
TW200423938A (en) 2003-02-21 2004-11-16 Wyeth Corp 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury
RS53118B (sr) 2003-02-26 2014-06-30 Sugen Inc. Aminoheteroaril jedinjenja kao inhibitori protein kinaze
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
JP2007502329A (ja) 2003-05-23 2007-02-08 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド セルトラリン組成物
PL2392565T3 (pl) 2003-09-26 2014-08-29 Exelixis Inc Modulatory c-Met i sposoby stosowania
DK1675961T3 (da) 2003-10-24 2009-02-23 Oncalis Ag Fremgangsmåde til identifikation og/eller validering af receptortyrosinkinaseinhibitorer
FR2871158A1 (fr) 2004-06-04 2005-12-09 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
JPWO2006080450A1 (ja) 2005-01-27 2008-06-19 協和醗酵工業株式会社 Ｉｇｆ−１ｒ阻害剤
WO2006111035A1 (en) 2005-04-21 2006-10-26 Oncalis Ag Method for the identification of possibly harmful receptor tyrosine kinase (rtk) mutations and of inhibitors or medication directed against rtk mutantstitle
JP2008540622A (ja) 2005-05-16 2008-11-20 アストラゼネカ アクチボラグ 化合物
BRPI0614809A2 (pt) 2005-08-09 2011-04-12 Johannes Gutenberg Universitaet Mainz sensibilização de cánceres de pulmão resistentes a fármaco a inibidores de proteìna cinase
EP1966152A2 (en) 2005-12-20 2008-09-10 Takeda Pharmaceutical Company Limited Glucokinase activators
DE102006030479A1 (de) 2006-07-01 2008-03-20 Merck Patent Gmbh Indazolderivate
JP5185930B2 (ja) 2006-07-07 2013-04-17 ブリストル−マイヤーズ スクイブ カンパニー ピロロトリアジンキナーゼ阻害剤
US7790756B2 (en) 2006-10-11 2010-09-07 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
HRP20141260T1 (xx) 2006-12-08 2015-03-13 Irm Llc Spojevi i sastavi kao inhibitori kinaze proteina
BRPI0720059A2 (pt) 2006-12-11 2013-12-17 Irm Llc Compostos e composições como inibidores de cinase
SI2120932T1 (sl) * 2006-12-20 2014-09-30 Nerviano Medical Sciences S.R.L. Indazolni derivati kot kinazni inhibitorji za zdravljenje raka
EP2173338A1 (en) 2007-07-06 2010-04-14 OSI Pharmaceuticals, Inc. Combination anti-cancer therapy
SI2176231T1 (sl) 2007-07-20 2017-01-31 Nerviano Medical Sciences S.R.L. Substituirani indazolni derivati, aktivni kot kinazni inhibitorji
CA2697795C (en) 2007-08-29 2016-08-16 Methylgene Inc. Thieno[3,2,b]pyridinyl compounds as inhibitors of protein tyrosine kinase activity
KR102037619B1 (ko) 2008-10-22 2019-10-28 어레이 바이오파마 인크. ＴＲＫ 키나아제 억제제로서 치환된 피라졸로［１,５­ａ］ 피리미딘 화합물
CN102924479A (zh) 2011-08-09 2013-02-13 山东鲁北药业有限公司 一种星孢菌素类衍生物的半合成方法
WO2013119950A2 (en) 2012-02-08 2013-08-15 Insight Genetics, Inc. Methods and compositions relating to fusions of ros1 for diagnosing and treating cancer
NZ627900A (en) 2012-03-06 2016-08-26 Pfizer Macrocyclic derivatives for the treatment of proliferative diseases
EP3333166B1 (en) 2012-05-23 2019-11-06 Nerviano Medical Sciences S.R.L. Process for the preparation of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
US20140107107A1 (en) 2012-09-28 2014-04-17 Oncoethix Sa Pharmaceutical formulation containing thienotriazolodiazepine compounds
WO2014093750A1 (en) 2012-12-14 2014-06-19 Glaxosmithkline Llc Method of administration and treatment
DE102013012850B4 (de) * 2013-08-02 2025-09-11 Sew-Eurodrive Gmbh & Co Kg Elektromotor mit Rotorwelle und Gehäuseteil
TWI672141B (zh) 2014-02-20 2019-09-21 美商醫科泰生技 投予ｒｏｓ１突變癌細胞之分子
HRP20191593T1 (hr) 2014-05-15 2019-11-29 Array Biopharma Inc 1-((3s,4r)-4-(3-fluorfenil)-1-(2-metoksietil)pirolidin-3-il)-3-(4-metil-3-(2-metilpirimidin-5-il)-1-fenil-1h-pirazol-5-il)urea kao inhibitor trka kinaze
US20170114415A1 (en) * 2014-05-30 2017-04-27 The Regents Of The University Of Colorado, A Body Corporate Activating ntrk1 gene fusions predictive of kinase inhibitor therapy
KR20170016858A (ko) 2014-06-13 2017-02-14 온코에틱스 게엠베하 티에노트리아졸로디아제핀 화합물을 사용하는 비소세포성 폐암 및/또는 소세포성 폐암의 치료 방법
AU2015355220B2 (en) 2014-12-02 2020-02-27 Ignyta, Inc. Combinations for the treatment of neuroblastoma
US20170356918A1 (en) 2014-12-03 2017-12-14 Ignyta, Inc. Multiplexed immunohistochemistry assays for diagnosis and treatment of cancer
AU2016270321B2 (en) 2015-05-29 2020-09-10 Ignyta, Inc. Compositions and methods for treating patients with RTK mutant cells
BR112017025773A2 (en) 2015-06-01 2018-08-14 Loxo Oncology, Inc. cancer diagnosis and treatment methods
CN108697708A (zh) 2015-10-26 2018-10-23 洛克索肿瘤学股份有限公司 Trk抑制剂抗性癌症中的点突变以及与此相关的方法
EP3389645A4 (en) 2015-12-18 2019-12-18 Ignyta, Inc. COMBINATIONS FOR TREATING CANCER
JP7203083B2 (ja) 2017-07-19 2023-01-12 イグナイタ インコーポレイテッド エントレクチニブを含む薬学的組成物
JP7311498B2 (ja) 2017-10-17 2023-07-19 イグナイタ インコーポレイテッド 薬学的組成物および剤形

Also Published As

Publication number Publication date
EA201691151A1 (ru) 2017-01-30
CA2933623C (en) 2022-05-17
NZ722405A (en) 2021-03-26
CL2016001507A1 (es) 2017-02-10
IL246544B (en) 2019-12-31
US20170007599A1 (en) 2017-01-12
ES2856231T3 (es) 2021-09-27
NL301111I1 (es) 2021-06-23
SG11201605816TA (en) 2016-08-30
KR102634514B1 (ko) 2024-02-07
KR20220165787A (ko) 2022-12-15
MX373042B (es) 2020-06-19
EP3107541B1 (en) 2020-12-23
IL246544A0 (en) 2016-08-31
CA2933623A1 (en) 2015-08-27
US10231965B2 (en) 2019-03-19
BR112016015818A2 (pt) 2017-08-08
TWI672141B (zh) 2019-09-21
US10561651B2 (en) 2020-02-18
PH12016501394A1 (en) 2017-02-20
EP3107541A1 (en) 2016-12-28
JP2017506255A (ja) 2017-03-02
NL301111I2 (nl) 2021-09-27
EA033457B1 (ru) 2019-10-31
CN106029073A (zh) 2016-10-12
KR20160117611A (ko) 2016-10-10
US10682348B2 (en) 2020-06-16
US20150283132A1 (en) 2015-10-08
JP6636933B2 (ja) 2020-01-29
AU2015220832A1 (en) 2016-09-08
PL3107541T3 (pl) 2021-09-20
UA118773C2 (uk) 2019-03-11
AU2015220832B2 (en) 2020-02-27
EP3834827A1 (en) 2021-06-16
US20180333412A1 (en) 2018-11-22
WO2015124697A1 (en) 2015-08-27
AU2015220832A2 (en) 2016-09-08
TW201613593A (en) 2016-04-16
US20190282564A1 (en) 2019-09-19

Similar Documents

Publication Publication Date Title
MX2016010519A (es) Moleculas para administracion a celulas cancerosas mutantes ros1.
CO2017000912A2 (es) Derivados de 2 -h indazol como inhibidores de kinasas dependientes de ciclinas (cdk) y usos terapeuticos de los mismos
CY1122566T1 (el) Παραγωγο 6,7,8,9-tetpaϋδpo-3h-πυραζολo[4,3-f] ισοκινολινης χρησιμο στη θεραπευτικη αντιμετωπιση του καρκινου
CY1122730T1 (el) 1,2,4-τριαζολες ως διαμορφωτες πυρηνικης μεταφορας και χρησεις αυτων
MX2017016344A (es) Compuestos de benzoxacepina oxazolidinona y metodos de uso.
MX379155B (es) Compuestos que inhiben la proteína mcl-1.
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
ECSP109934A (es) Compuesto - 946
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
DK2324008T3 (da) Diarylpyrazol som protein kinase inhibitorer
DOP2010000012A (es) Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k
CO2019009722A2 (es) Dendrímeros terapéuticos
CL2019002900A1 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
UY32190A (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibdores de quinasas dependientes de ciclina (cdk), produccion y uso de los mismos como productos medicinales
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
MX2017001603A (es) Derivados de piperazina como moduladores de los receptores x del higado.
MX368735B (es) (r)-pirlindol y sus sales farmaceuticamente aceptables para uso en medicina.
PH12020500436A1 (en) Aromatic derivative, preparation method for same, and medical applications thereof
EA201891027A1 (ru) Фармацевтическая композиция, содержащая производные индола, способ ее получения и применение
AR105921A1 (es) Compuestos terapéuticos para el dolor y síntesis de estos
CU20100005A7 (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
CU20100003A7 (es) Derivados trisustituídas de pirimidina para el tratamiento de enfermedades proliferativas

Legal Events

Date Code Title Description
FG Grant or registration